Kestra Medical Technologies (KMTS) Cost of Revenue (2024 - 2026)

Kestra Medical Technologies (KMTS) has 3 years of Cost of Revenue data on file, last reported at $13.0 million in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 34.96% year-over-year to $13.0 million in Q2 2026; TTM through Apr 2026 was $46.3 million, a 29.93% increase from a year earlier, with the FY2026 full-year figure at $46.3 million, up 29.93% from the prior year.
• Cost of Revenue for Q2 2026 stood at $13.0 million, up from $11.6 million in the prior quarter.
• Over the last five years, Cost of Revenue for KMTS reached as high as $13.0 million in Q2 2026 and fell as low as $7.4 million in Q1 2024.
• Historically, Cost of Revenue has averaged $9.8 million across 3 years, with a median of $9.2 million in 2024.
• Across the five-year window, Cost of Revenue climbed 10.89% in 2025 and surged 36.32% in 2026, its largest moves.
• Year by year, Cost of Revenue stood at $8.9 million in 2024, then rose by 25.46% to $11.1 million in 2025, then increased by 16.29% to $13.0 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $13.0 million in Q2 2026, $11.6 million in Q1 2026, and $11.1 million in Q4 2025.